Молодежный инновационный вестникМолодежный инновационный вестник2415-7805Федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации10026Conference ProceedingsDetermination of galectin-3 marker in patients with chronic heart failureKolpachevaMarinamarina.kolpacheva.1997@mail.ruShevtsovaVeronikashevvi17@yandex.ruhttps://orcid.org/0000-0002-1707-436XVoronezh State Medical University named after N.N.Burdenko2712202413265661604202417062024Copyright © 2024, Kolpacheva M., Shevtsova V.2024<p>Chronic heart failure (CHF) has been an urgent problem in medicine for many years. Body composition of patients with CHF is one of the determinants of prognosis. Galectin-3 is a marker reflecting pathophysiologic changes in CHF, its level also changes with changes in body composition of patients. The aim of the study was to investigate the level of galectin-3 and the course of the disease in patients with CHF and different nutritional status. It was determined that III (FC) of CHF is more common in patients with sarcopenic obesity, reduced body weight and sarcopenia. Obese patients, regardless of the presence of sarcopenia were characterized by HFpEF. Galectin-3 levels were minimal in patients with reduced body weight and maximal in sarcopenic obese patients.</p>chronic heart failure, sarcopenic obesity, sarcopenia, nutritional status, galectin-3хроническая сердечная недостаточность, саркопеническое ожирение, саркопения, нутритивный статус, галектин-3<p><strong>Introduction.</strong> Patients with CHF are characterized by different nutritional status. Obesity, being a risk factor for CVD, is common in patients with CHF [1]. Sarcopenia is also common in patients with CHF, since the average age is about 70 years [2].</p> <p>Due to its influence on cardiac remodeling, galectin-3 is important in the pathophysiology of CHF [3]. Galectin-3 is known to be an independent predictor of all-cause mortality or hospitalization for heart failure [4].</p> <p>The aim of the work was to study the level of galectin-3 in patients with CHF depending on body composition.</p> <p><strong>Materials and methods of the study.</strong> 298 people took part in the study. All patients were questioned using SARC-F questionnaire, carpal dynamometry, bioimpedancemetry, "4 m walking speed" test, 6-minute walk test, clinical status assessment scale (CSA) was performed, ejection fraction parameters and galectin-3 biomarker level were studied.</p> <p>Patients were divided into 5 groups depending on body weight and the presence of sarcopenia.</p> <p><strong>Materials and methods of the study.</strong> 298 people took part in the study. All patients were questioned using the SARC-F questionnaire, carpal dynamometry, bioimpedancemetry, "4 m walking speed" test, 6-minute walking test, clinical status assessment scale (CSAS) was performed, ejection fraction and galectin-3 biomarker level were studied.</p> <p>Patients were divided into 5 groups depending on body weight and the presence of sarcopenia.</p> <p><strong>Results of the study.</strong> At the first stage it was determined that FC II was more frequent in the third group; FC III was less frequent in the third group; FC IV was more frequent in the first group.</p> <p>The study revealed statistically significant differences by ejection fraction in patients: in groups 4 and 5 (obese patients) prevailed values characteristic for CHF with preserved ejection fraction.</p> <p>The worst TSH values (Me 153 [68-170] m/s) were revealed in the first group. At the same time, the index values in the group of patients with sarcopenic obesity (Me 192 [159,5-319,5] ng/mL) were lower than in patients without obesity and sarcopenia, as well as in patients with obesity and sarcopenia only.</p> <p>The values of galectin-3 level in group 1 (Me 16 [11-17] ng/mL) were minimal and statistically significantly different from those in other groups. The maximum values were determined in group 4 patients (with sarcopenic obesity) - Me 36 [30.25-39] ng/mL.</p> <p><strong>Conclusion: </strong>Patients with sarcopenic obesity and with reduced body weight and sarcopenia more often have class III CC of CHF. Galectin-3 levels were significantly higher in the group of patients with sarcopenic obesity and significantly lower in patients with reduced body weight and sarcopenia.</p>1.Murphy S.P, Ibrahim N.E, Januzzi J.L. Heart Failure with Reduced Ejection Fraction: A Review. JAMA – 2020. - 324(5):488-504. doi:10.1001/jama.2020.10262.2.Фомин И.В. Эпидемиология хронической сердечной недостаточности в Российской Федерации. В кн.: Хроническая сердечная недостаточность - М.: ГЭОТАР-Медиа - 2010. - с. 7 - 77.3.Стенхольм С., Харрис Т.Б., Рантанен Т., Виссер М., Кричевский С.Б., Ферруччи Л. Саркопеническое ожирение: определение, причина и последствия. Curr Opin Clin Nutr Metab Care - 2008. - №11. - p. 693–700.4.Nurjannah N, Nurahmi N, Kurniawan LB. Correlation Analysis of Galectin-3 Serum Level in Obesity with and without Obesity. Indonesian J. Clin. Pathol. Med. Lab. 2023; 29(3): 216–219. DOI: 10.24293/ijcpml.v29i3.2048.5.Sygitowicz G, Maciejak-Jastrzębska A, Sitkiewicz D. The Diagnostic and Therapeutic Potential of Galectin-3 in Cardiovascular Diseases. Biomolecules. 2022; 12(1): 46. DOI: 10.3390/biom12010046.